Alnylam Pharmaceuticals reported $-188331000 in Pre-Tax Profit for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -43.4M 23.03M
Agios Pharmaceuticals AGIO:US $ -82.79M 8.09M
Alexion Pharmaceuticals ALXN:US $ 940.1M 164.6M
Alnylam Pharmaceuticals ALNY:US $ -188.33M 10.94M
Arena Pharmaceuticals ARNA:US $ -146.1M 27.68M
Arrowhead Research ARWR:US $ -29.92M 3.11M
Bluebird Bio BLUE:US $ -231.42M 25.67M
Dicerna Pharmaceuticals DRNA:US $ -40.27M 10.3M
Intercept Pharmaceuticals ICPT:US $ -11.09M 29.33M
IONIS PHARMACEUT IONS:US $ -81M 8.74M
Moderna Inc MRNA:US 3.06B 1.8B
Neurocrine Biosciences NBIX:US $ 57.5M 30.3M
Novartis NVS:US $ 4424M 361M
Ptc Therapeutics PTCT:US $ -117.88M 10.31M
Regeneron Pharmaceuticals REGN:US $ 3898.3M 2658.7M
Regulus Therapeutics RGLS:US $ -6.03M 0.02M
Sangamo Biosciences SGMO:US $ -47.15M 1.47M
Sarepta Therapeutics SRPT:US $ -81.76M 85.63M
Ultragenyx Pharmaceutical RARE:US $ -121.96M 13.8M
Xencor XNCR:US $ 52.25M 54.74M
YTE INCY:US $ 199.6M 31.06M